Seattle, United States
Monod Bio, established in 2021, is a trailblazing entity in the realms of Biotechnology, Health Care, and Life Sciences. Known for their slogan, "Simple and powerful biosensors for medicine and biotechnology," the company is headquartered in the United States.
At the core of Monod Bio's innovation is their cutting-edge de novo protein biosensor platform, which leverages the latest in computational protein engineering to fabricate versatile biosensing nanoswitches. These nanoswitches are designed to facilitate rapid, sensitive, and cost-efficient analytical assays, positioning the company at the leading edge of biosensor technology.
The startup has garnered robust financial backing; it secured a substantial $25.00M Seed Round on 15 August 2022. The round was financed by a consortium of investors, including Boom Capital Ventures, Sahsen Ventures, Matrix Capital Management, Global Health Investment Fund (GHIF), Washington Research Foundation, Cercano Management, and Pack Ventures.
